Osimertinib Study in Indian Patients
NCT03853551
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
DRUG:
Osimertinib
Sponsor
AstraZeneca